Alexion (ALXN) has done what so few biotechs ever manage to do. Not only has the company successfully developed a drug, it has stayed independent and achieved profitability on its own. Now the company is in that tricky area grey area between biotech and pharma, an area that can be dangerous to valuations and new investors.
Soliris A Powerful Engine
The Alexion story today is all about Soliris, the company's drug for paroxysmal noctural hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). PNH and aHUS are uncommon diseases, but like Genzyme (before it was acquired by Sanofi (SNY)), Alexion has built a lucrative franchise around a unique drug that commands incredible pricing.
Please click here for more:
Alexion Pharmaceuticals: A Tricky Mix Of Biotech And Pharma
No comments:
Post a Comment